(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Former Israeli judge does not expect Netanyahu to be pardoned - 2Italy now recognizes the crime of femicide and punishes it with life in prison
- 3Vote in favor of the bloom plan that adds a bit of excellence to your life!
- 4This Miraculous, Cliff-Perched Town In The South Of France Is A Sacred European Gem
- 5James Webb Space Telescope watches our Milky Way galaxy's monster black hole fire out a flare
- OECD: Iran war dampening global growth
- Germany's first Omani LNG shipments arrive despite Middle East disruptions
- Christmas 2025 skywatching guide: What you can see in the night sky on Dec. 25
- 19 Strange Motion pictures You Shouldn't Watch With Your Mum
- Enormous Credit And All that You Really want To Be aware
- From candy cane fishing to ornament switcharoo, here are some of the best games you can play with your loved ones this holiday season
- Scientists document a death from a meat allergy tied to certain ticks
- Online business Stages for Little Retailers
- 4 Excellent Remote Headphones of 2024
